Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer

被引:1
|
作者
Fang, Yutong [1 ,2 ]
Zhang, Qunchen [3 ]
Chen, Zexiao [1 ,2 ]
Guo, Cuiping [1 ,2 ]
Wu, Jundong [1 ,2 ]
机构
[1] Shantou Univ, Canc Hosp, Med Coll, Breast Ctr, Shantou 515041, Guangdong, Peoples R China
[2] Shantou Univ, Canc Hosp, Med Coll, Dept Cent Lab, Shantou 515041, Guangdong, Peoples R China
[3] Jiangmen Cent Hosp, Dept Breast, Jiangmen 529000, Guangdong, Peoples R China
来源
AGING-US | 2024年 / 16卷 / 01期
关键词
breast cancer; miR-221-3p; epithelial-mesenchymal transition; target gene; diagnosis; prognosis; immune; TUMOR-GROWTH; C-KIT; EXPRESSION; EMT; CELLS; MMP14; ASSOCIATION; PROGRESSION; METASTASIS; MIGRATION;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: MicroRNA-221-3p (miR-221-3p) facilitates the advancement of breast cancer (BC) through the induction of epithelial-mesenchymal transition (EMT). Our research aimed to utilize bioinformatics to discover possible EMT-related target genes (ETGs) of miR-221-3p and examine their roles in breast cancer. Methods: We employed bioinformatics techniques to identify ten key ETGs of miR-221-3p. Subsequently, we conducted an extensive analysis of both miR-221-3p and the ten ETGs, including clinical significance and immune characteristics. Results: The expression of miR-221-3p was notably higher in Basal-like BC compared to other subtypes and adjacent normal tissue. Our pathway analysis suggested that miR-221-3p might regulate EMT through the MAPK signaling pathway by targeting its ETGs. Among the ETGs, seven core genes (EGFR, IGF1, KDR, FGF2, KIT, FGFR1, and FGF1) exhibited downregulation in BC. Conversely, ERBB2, SDC1, and MMP14 showed upregulation in BC and displayed potential diagnostic value. The analysis of prognostication indicated that increased levels of SDC1 and MMP14 were correlated with an unfavorable prognosis, whereas elevated expression of KIT was associated with a more favorable prognosis. The infiltration of various immune cells and the expression of immune checkpoint genes (ICGs) exhibited positive correlations with most ETGs and miR-221-3p. SDC1 exhibited a greater tumor mutational burden (TMB) score, while ERBB2, KDR, FGF2, KIT, FGFR1, and FGF1 showed lower TMB scores. Furthermore, decreased ERBB2 and KDR expression levels were correlated with elevated microsatellite instability (MSI) scores. Elevated expression of ETGs was linked to decreased mRNA stemness indices (mRNAsi), whereas miR-221-3p displayed the opposite pattern. Most ETGs and miR-221-3p expression exhibited a negative correlation with IC50 values for drugs. Among the ETGs, amplification was the most significant genetic alteration, except for IGF1. Conclusion: In conclusion, miR-221-3p acts as a unique indicator for Basal-like BC. The examination revealed ten essential ETGs of miR-221-3p, some of which show potential as diagnostic and prognostic markers. The in-depth examination of these ten ETGs and miR-221-3p indicates their participation in the development of BC, emphasizing their promise as innovative targets for therapy in BC patients.
引用
收藏
页码:322 / 347
页数:26
相关论文
共 50 条
  • [21] MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock 1
    Li, Hongli
    Mou, Qingjie
    Li, Peirui
    Yang, Zhiyi
    Wang, Zhaoyan
    Niu, Jie
    Liu, Yuanyuan
    Sun, Zhiliang
    Lv, Shijun
    Zhang, Baogang
    Yin, Chonggao
    JOURNAL OF CANCER, 2019, 10 (19): : 4695 - 4706
  • [22] Hypoxia-related miR-210-5p and miR-210-3p regulate hypoxia-induced migration and epithelial-mesenchymal transition in hepatoma cells
    Li, Xin
    Wu, Hong
    Wu, Manya
    Feng, Yan
    Wu, Susu
    Shen, Xiaoyun
    He, Jintao
    Luo, Xiaoling
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (05): : 5096 - 5104
  • [23] Hypoxia-Induced Downregulation of MiR-199a-3p Promotes Proliferation, Invasion and Epithelial-Mesenchymal Transition in Colorectal Cancer Cells
    Lin, Limiao
    Chen, Bihong
    Li, Yanqing
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2022, 36 (05): : 1501 - 1509
  • [24] Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast Cancer
    Creighton, Chad J.
    Chang, Jenny C.
    Rosen, Jeffrey M.
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2010, 15 (02) : 253 - 260
  • [25] Substrate stiffness affects epithelial-mesenchymal transition of cervical cancer cells through miR-106b and its target protein DAB2
    Piao, Jinlan
    You, Ke
    Guo, Yanli
    Zhang, Youyi
    Li, Zijian
    Geng, Li
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 50 (06) : 2033 - 2042
  • [26] miR-105-5p/PTEN Axis Modulates the Immune Response and Epithelial-Mesenchymal Transition of Colon Cancer via NF-κB Activation
    Yao, Fei
    Hu, Biwen
    Li, Senjuan
    Cao, Chenxi
    Ling, Yiting
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2025, 39 (01)
  • [27] Overexpression of miR-328-3p Inhibits Epithelial-Mesenchymal Transition in Prostate Cancer by Downregulating PFN1
    Gu, Zhenhua
    Li, Jianzhong
    Yang, Yucheng
    Ding, Rui
    Wang, Meili
    Chen, Jian
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2024, : 2240 - 2257
  • [28] Trail Resistance Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness by Suppressing PTEN via miR-221 in Breast Cancer
    Wang, Haiji
    Xu, Chunyuan
    Kong, Xiaoli
    Li, Xiaoyan
    Kong, Xiangnan
    Wang, Yu
    Ding, Xia
    Yang, Qifeng
    PLOS ONE, 2014, 9 (06):
  • [29] Sevoflurane Suppresses the Migration, Invasion, and Epithelial-Mesenchymal Transition of Breast Cancer Cells Through the miR-139-5p/ARF6 Axis
    Wu, Tongle
    Sun, Luwei
    Wang, Chuantao
    Yu, Peng
    Cheng, Long
    Chen, Yongmin
    JOURNAL OF SURGICAL RESEARCH, 2021, 258 : 314 - 323
  • [30] Nonylphenol promotes epithelial-mesenchymal transition in colorectal cancer cells by upregulating miR-151a-3p
    Wang, Biao
    Zhang, Nianjie
    Dai, Lin
    Zhang, Yuanwei
    Yin, Shuo
    Yang, Xuefeng
    DISCOVER ONCOLOGY, 2025, 16 (01)